Effects of rabeprazole on acute exacerbation in chronic obstructive pulmonary disease (COPD) patients with acid reflux symptoms

Effects of rabeprazole on acute exacerbation in chronic obstructive pulmonary disease (COPD) patients with acid reflux symptoms - Effects of rabeprazole on acute exacerbation in COPD patients with acid reflux symptoms

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002056

Enrollment

Registered

2009-06-10

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease

Interventions

Rabeprazole 10mg per day for a year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic obstructive pulmonary disease patients and gastroesophageal reflux diagnosed with QUEST questionnaire.

Exclusion criteria

Exclusion criteria: 1.Patients treated with gastric secretion inhibitor in a month prior to this study. 2.Patients with active peptic ulcer or Zollinger-Ellison syndrome. 3.Patients with malignancy. 4.Patients with cardiac, hepatic or hematologic disease.

Design outcomes

Primary

Measure	Time frame
Frequency of acute exacerbation of chronic obstructive pulmonary disease in a year	—

Secondary

Measure	Time frame
Frequency of common cold in a year	—

Countries

Japan

Contacts

Public ContactTakahiko Sasaki

Tohoku University Hospital Department of Respiratory Medicine

022-717-8539

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026